Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 1,743 trials

Metastatic Colorectal Cancer: Tinzaparin for Blood Clot Prevention

We are studying whether tinzaparin can help prevent blood clots in patients with metastatic colorectal cancer starting their first line of treatment. This may help reduce the risk of complications related to blood clots.

Metastatic Colorectal CancerThromboembolic Event>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOncology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Rivaroxaban Monotherapy Study

We are exploring the safety of rivaroxaban in patients with atrial fibrillation who have had a heart procedure. This study aims to see if this treatment is a viable option for these patients.

Coronary Artery DiseasePercutaneous Coronary InterventionAtrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Graft-Versus-Host Disease Prevention: CY-MET-RIC Study

We are testing two different treatment plans to see which better prevents severe graft-versus-host disease in patients receiving matched-donor transplants. This study will also evaluate overall survival and other important health outcomes.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Advanced Solid Tumors: AMG 355 Treatment Study

We are exploring a new treatment called AMG 355, both alone and with Pembrolizumab, for individuals with advanced solid tumors. This study aims to assess its safety and potential effectiveness.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant

We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.

Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

B-Cell Cancer: INT2104 Infusions

We are investigating the safety of INT2104 infusions for adults with B-cell cancers that have returned after previous treatments. This study aims to understand how well this new treatment works in this patient group.

Refractory B-Cell Malignancies>2 yearsSafety phase (I)Oncology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Mevrometostat for Relapsed/Refractory Cancers

We are testing Mevrometostat in patients with relapsed or refractory small cell lung cancer, castration-resistant prostate cancer, and follicular lymphoma. The goal is to see how well it works in these challenging cases.

Castration Resistant Prostate CancerSmall Cell Lung CancerFollicular Lymphoma>2 yearsSafety phase (I)HematologyOncology